Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell–Mediated Angioedema

Marcus Maurer · Markus Magerl

Accepted: 13 January 2021 / Published online: 3 February 2021
© The Author(s) 2021

Abstract
Angioedema (AE), transient localized swelling due to extravasated fluid, is commonly classified as mast cell mediator-induced, bradykinin-mediated or of unknown cause. AE often occurs more than once, and it is these recurrent forms of AE that are challenging for patients and physicians, and they are the ones we focus on and refer to as AE in this review. Since effective treatment depends on the causative mediator, reliable and early diagnosis is essential. Although their clinical presentations bear similarities, many forms of angioedema exhibit specific patterns of clinical appearance or disease history that may aid in diagnosis. Here, we describe the most common differences and similarities in the mechanisms and clinical features of bradykinin-mediated and mast cell mediator-induced types of angioedema. We first provide an overview of the diseases that manifest with mast cell mediator-induced versus bradykinin-mediated angioedema as well as their respective underlying pathogenesis. We then compare these diseases for key clinical features, including angioedema location, course and duration of swelling, attack frequency, prevalence and relevance of prodromal signs and symptoms, triggers of angioedema attacks, and other signs and symptoms including wheals, age of onset, and duration. Our review and comparison of the clinical profiles of different types of angioedema incorporate our own clinical experience as well as published information. Our aim is to highlight that mast cell mediator-induced and bradykinin-mediated angioedema types share common features but are different in many aspects. Knowledge of the differences in underlying pathomechanisms and clinical profiles between different types of angioedema can help with the diagnostic approach in affected patients and facilitate targeted and effective treatment.

Keywords Angioedema · Bradykinin · Mast cell · Hereditary angioedema · Urticaria

Abbreviations
ACEi Angiotensin converting enzyme inhibitors
AE Angioedema
ANGPT1-HAE HAE with angiopoietin mutation
AsU/CsU Acute/chronic spontaneous urticaria
BK-AE Bradykinin-induced angioedema
BK Bradykinin
CSU Chronic spontaneous urticaria
ClndU Chronic inducible urticaria
C1-INH C1 Esterase Inhibitor
C1-INH-AAE Angioedema due to acquired C1-INH deficiency
C1-INH-HAE HAE with C1-INH deficiency
cHK Cleaved HK
FXII Coagulation Factor 12 (Hageman factor)
FXII-HAE HAE with Factor XII mutation
HAE Hereditary angioedema
HK High molecular kininogen
IgE Immunoglobulin E
KNG1-HAE HAE with kininogen 1 mutation
MCM-AE Mast cell mediator-induced angioedema
MYOF-HAE HAE with myoferlin mutation
nC1-INH-HAE HAE with normal C1-INH
PK PreKallikrein (Fletcher factor)
PKa Plasma kallikrein
PLG-HAE HAE with plasminogen mutation
RAAS Renin–angiotensin–aldosterone system
tPA Tissue plasminogen activator
Clinical Reviews in Allergy & Immunology (2021) 61:40–49

Introduction

Angioedema (AE) is defined as a transient localized swelling due to extravasated fluid. In clinical terms, AE is often a chronic disease with swellings that occur more than once rather than a solitary episode of swelling. The latter are mostly allergic reactions, for example, in the context of anaphylaxis due to allergen exposure. Here, we focus on AE forms that manifest with recurrent swellings, as they are the ones that are challenging for patients and physicians, and we use the term AE to refer to these recurrent forms of AE.

AE virtually always involves the lower layers of the skin (dermis) and the highly vascular subcutis or the mucous membranes, lasting from a few hours up to several days. In most cases, angioedema occurs spontaneously, but may be induced by various “triggers” [1]. In patients with AE, i.e., repeated angioedema attacks for longer than 6 weeks, swelling episodes are separated from each other by symptom-free intervals of a variable duration. Angioedema of the skin is non-pitting, frequently asymmetric, mostly non-pruritic, and can be rather painful. Depending on its location, AE can cause disfigurement, physical dysfunctionality, pain, or obstruction of airways, thereby impairing patients’ quality of life.

AE is commonly classified as mast cell mediator-induced AE (MCM-AE), bradykinin (BK)-mediated AE (BK-AE), and AE of unknown cause, based on the underlying pathogenesis. Here, we describe differences and similarities in the mechanisms and clinical features of MCM-AE and BK-AE.

Forms of Mast Cell-Mediated AE and Underlying Pathogenesis

Diseases that Manifest with MCM-AE

Chronic urticaria is by far the most common disease that manifests with MCM-mediated AE [2]. AE in patients with chronic urticaria more often occurs in those with chronic spontaneous urticaria (CSU) than chronic inducible urticaria (CIndU). CSU is a common disease with a prevalence of up to 1.4% in the general population [3]. It is defined by the recurrent occurrence of wheals, angioedema, or both. AE, with or without wheals, occurs in up to 70% of patients with CSU [4, 5], and around 10% of CSU patients only have AE without wheals [6]. In CSU, AE is linked to prolonged disease duration and high burden of disease [7]. However, AE is less common in patients with CIndU (such as cold or cholinergic urticaria). In a recent study, 46% of patients with cholinergic urticaria (CholU), a CIndU characterized by perspiration-induced signs and symptoms, had AE [8]. Cholinergic urticaria (CholU) patients with AE were significantly more likely to have a prolonged disease duration and to experience extracutaneous signs and symptoms than CholU patients without AE. In symptomatic dermatographism, a CIndU with scratching-induced signs and symptoms, one in five patients reports AE, mostly localized to the eyelids, legs, and hands [9]. The rates and relevance of AE in other CIndUs are less well characterized. Outside of chronic urticaria MCM-AE may also occur in the context of anaphylaxis.

The Pathogenesis of MCM-AE

Mast cells are organ-resident cells of the innate and adaptive immune system [10, 11]. Their main physiological role is to provide a first line of defense against pathogens and other environmental threats [12–14]. In the skin, mast cells are co-localized with sensory nerves and small blood vessels. Mast cell activation and the subsequent release of preformed mediators, including histamine and proteases, induce sensory nerve stimulation (pruritus, burning sensation, pain), vasodilatation (erythema), increased plasma extravasation (edema) and the recruitment of eosinophils, basophils, and other immune cells (cellular infiltrate). Mast cell activation is a complex process that is initiated by a large array of signals, many of which act via specific mast cell surface receptors. Prominent mast cell-activating receptors include the high affinity IgE receptor FceRI, receptors for the complement components C3a and C5a, and the Mas-related G-protein coupled receptor member X2 (MRGPRX2) [15].

In chronic urticaria, angioedema and wheals are induced by the degranulation of mast cells and the effects of the mediators they release, mainly histamine. Histamine acts on H1 receptors located on vascular endothelial cells to cause extravasation (wheels and angioedema) and on sensory nerves, resulting in neurogenic flare (erythema) and pruritus. Effects on H2 and H4 receptors may also be involved. Several other mediators of the mast cell, like leukotrienes, or the platelet activating factor can cause similar responses to histamine, and thereby amplify and prolong the inflammatory process. Importantly, the recruitment of inflammatory cells to skin sites of mast cell activation and degranulation, in most forms of chronic urticaria, contributes to the features of wheals and angioedema and primes the skin for subsequent whealing and angioedema development [16, 17].

In terms of the signals that contribute to skin mast cell activation and degranulation in chronic urticaria and, therefore, angioedema and wheal development, true mast cell degranulators need to be distinguished from mast cell...
modulators. The first lead to degranulation and are therefore essential for the release of proinflammatory mast cell mediators and subsequent development of angioedema. Mast cell modulators alter the skin mast cells threshold, and therefore augment their response to mast cell degranulators [18].

Two different classes of autoimmune antibodies lead to skin mast cell degranulation in CSU [19]: (a) Specific IgE antibodies against autoantigens [20–22] and (b) IgG and IgM autoantibodies against IgE or the alpha subunit of the IgE receptor [23, 24]. Infection-associated signals, food components, and neuropeptides are seen today, as relevant mast cell modulators. Mental stress is also regarded as a relevant modulator of CSU disease activity in many patients. Neuropeptides that are released during stress reactions have mast cell-modulating effects.

Forms of BK-Mediated AE and Underlying Pathogenesis

Diseases that Manifest with BK-AE

BK-AE occurs in hereditary angioedema (HAE) with or without C1 inhibitor (C1-INH) deficiency, AE due to acquired C1-INH deficiency (C1-INH-AAE), and angiotensin-converting enzyme inhibitor (ACEi)-associated AE. In general, most of these diseases present with AE in the absence of wheals are considered rare diseases, except ACEi-associated AE (due to a very high global usage of ACEi) [1, 25].

Hereditary angioedema due to C1-INH deficiency (C1-INH-HAE): This is the most common form of HAE and results from a quantitative (Type 1, approximately 85% of patients) or functional (Type 2, approx. 15%) deficiency of C1-INH, the main plasma serine-protease inhibitor of the BK-forming system. Both type 1 and 2 C1-INH-HAE are caused by mutations in the C1-INH gene, SERPING1, and are inherited as autosomal dominant trait. However, the percentage of spontaneous mutations (new mutations) is high at approximately 20%. The minimal prevalence of HAE is 1:67,000 in the general population, without evidence of any gender, ethnic, or racial differences [1, 25–27].

Hereditary angioedema with normal C1-INH (nC1-INH-HAE): The clinical appearance of nC1-INH-HAE resembles that of C1-INH-HAE; however, most patients are female, and their C1-INH and plasma complement levels are normal. As of now, mutations in 5 genes were found to be pathogenic: Factor XII (FXII) [28], plasminogen (PLG) [29], angiopoietin-1 (ANGPT1) [30], kininogen-1 (KNG1) [31], and myoferlin (MYOF) [32]. By now, more than 400 patients with FXII-HAE and more than 100 patients with PLG-HAE have been reported. Patients with ANGPT1-HAE, KNG1-HAE, and MYOF-HAE were only described in few individuals and families. FXII-HAE, PLG-HAE, and KNG1-HAE are considered to be bradykinin-mediated forms of AE, with excess formation of BK, whereas ANGPT1-HAE and MYOF-HAE are held to be due to vascular endothelial receptor modulation, respectively, VEGF signal transduction. Women are strikingly overrepresented amongst patients, and estrogen-sensitivity has been described very frequently in FXII-HAE and frequently in PLG-HAE [33]. It should be kept in mind that nC1-INH-HAE is an umbrella term for a variety of AE diseases, many of which are extremely rare, and clinical data are lacking at the present time. Therefore, the description and characterization of their clinical features as one disease are oversimplified.

AE due to acquired C1-INH deficiency (C1-INH-AAE): C1-INH deficiency can also be acquired. It occurs due to increased catabolism of C1-INH, when C1-INH degradation outperforms the synthesis of new C1-INH. Patients with C1-INH-AAE often have an underlying disease such as a lymphoproliferative disorder that leads to continuous activation of the classic complement pathway with consequent depletion of C1-INH. Some patients may also develop autoantibodies to C1-INH protein, which interferes with its level and activity. Like C1-INH-HAE, AE in patients with C1-INH-AAE has elevated plasma BK levels [34, 35].

Angiotensin converting enzyme (ACE) inhibitor-associated angioedema (ACEi-AE): ACE is a protease that cleaves BK. When ACE is inhibited, BK degradation is impaired, which facilitates the development of AE. Indeed, patients with ACEi-AE have been reported to have increased plasma BK levels. Dipeptidyl peptidase-4 inhibitors (DPPIV) or neprilysin (neutral endopeptidase) inhibitors used in the treatment of hypertension can increase the propensity of drug-induced angioedema significantly when combined with ACEi [36–38].

The Pathogenesis of BK-Mediated AE

BK is a vasoactive nonapeptide that promotes vasodilatation via the BK B2 receptor [39, 40]. The BK-forming cascade in the plasma, i.e., the contact system and kallikrein-kinin pathways, consists of activated factor XII(a), (pre) kallikrein (PK), kallikrein (PKa), and high-molecular-weight kininogen (HK). This cascade is initiated when FXII and PK are activated and form FXIIa and PKa, which cleaves HK to release BK [41, 42]. C1-INH regulates this cascade, by binding to the active sites of factor XIIa and kallikrein, thereby inactivating them. BK is degraded by ACE (kininase 2), carboxypeptidase N, neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P, resulting in extremely short half-life of 17 s [43, 44]. Both increased production
and inhibited degradation can cause excess of BK and subsequent angioedema.

**Differences and Similarities of MCM-AE and BK-AE**

MCM-AE and BK-AE are different in many aspects but also share common features (Table 1). Since the prognosis and treatment in patients with MCM-AE and BK-AE are fundamentally different, it is important to know how to tell the two apart [45]. Knowledge of these differences can help with the diagnosis and treatment of patients with AE.

**Differences and Similarities in Angioedema Features of MCM-AE and BK-AE**

**Angioedema Location**

All types of AE, MCM-AE, and BK-AE primarily involve the cutis/mucosa and subcutis/submucosa, affect several organs, and manifest in many locations of the body. The skin of the face, including the lips and the oral mucous membranes, is common location of swellings in all types of AE. MCM-AE and BK-AE show different patterns regarding their preferred localization, but there are also differences between the different types of BK-AE.

Involvement of the tongue, including isolated tongue swellings, is frequent in MCM-AE but also in most forms of nC1-INH-HAE, especially PLG-HAE, and in ACEi-AE. Isolated AE of the tongue is relatively rare in C1-INH-HAE and C1-INH-AAE [33, 46–48]. Clinical experience suggests that there is benefit in asking patients whether lip or tongue swellings begin unilaterally, as a unilateral onset of lip or tongue angioedema is more likely to occur in ACEi-AE and MCM-AE rather than in C1-INH-HAE or C1-INH-AAE.

Involvement of the larynx and oropharynx with the risk of asphyxiation and fatal outcome is predominantly seen in BK-AE, most of all in ACEi-AE and C1-INH-HAE. Up to 50% of patients with C1-INH-HAE experience laryngeal swellings, that if not treated, can lead to death by asphyxiation [49–52]. In MCM-AE, shortness of breath due to swellings of the upper airways (pharynx, tongue) can be seen in some cases, albeit very rarely, especially in chronic urticaria patients with MCM-AE. Laryngeal swellings with a fatal outcome have never been reported in chronic urticaria patients.

AE of the earlobes points to MCM-AE due to chronic urticaria. This location is usually described with redness and warming of the skin, along with itch or a burning sensation. Thus, AE of the earlobes, in patients with chronic urticaria, usually shares features of urticarial wheals. Ear swellings have also been reported in patients with FXII-HAE but appear to be rare in BK-AE [33].

Almost all patients with C1-INH-HAE experience swellings of the extremities, and by far the most swelling episodes are located in these skin regions [53]. Angioedema of the skin of the limbs occurs in MCM-AE as well as in BK-AE. Peripheral skin swellings, especially angioedema of the hands and feet, are typical for C1-INH-HAE. Swellings of the extremities are less common in patients with other types of BK-AE such as nC1-INH-HAE, and they are very rare in PLG-HAE and ACEi-AE [54]. In contrast, the skin

| Table 1 Overview of differences and similarities between MCM-AE and BK-AE |
|---------------------------------------------------------------|
| Recurrent laryngeal angioedema | ++ | ++ | ++ | ++ | - |
| Predominantly recurrent isolated tongue swelling | - | + (PLG) | - | ++ | + |
| Wheals present/history of recurrent wheals | - | - | - | - | ++ |
| Recurrent painful abdominal attacks | ++ | + | ++ | - | |
| Tongue/lip swellings, usually unilateral at onset | + | + | |
| Head/neck swelling onset usually early morning hours | + | | |
| Prodromal symptoms | ++ | - | - | - | - |
| Decade of symptom onset | 0-2 | 0-4 | >6 | >5 | >0 |
| Family history of recurrent angioedema and/or abdominal pain/deaths by asphyxiation | ++ | ++ | - | - | - |
| Mainly females in family history | - | ++ | - | - | - |
| Estrogen sensitivity | + | ++ | + | | |
| Angioedema repeatedly triggered by NSAID’s | - | - | - | - | + |

+: frequent or typical, ++: very frequent or very typical, -: rare or unusual, blank: indetermined or unknown

C1-INH-HAE HAE with C1-INH deficiency, nC1-INH-HAE HAE with normal C1-INH, C1-INH-AAE angioedema due to acquired C1-INH deficiency, ACEi / RAAS angioedema due to ACE-inhibitors and the renin–angiotensin–aldosterone system, AsU/CsU acute/chronic spontaneous urticarial, PLG plasminogen-gene mutation, NSAID nonsteroidal anti-inflammatory drugs.
of the limbs is often affected and is the second most frequent localization of swellings in patients with MCM-AE, second only to the skin of the head and neck.

Abdominal attacks, i.e., painful episodes of angioedema of the gut walls, are seen in almost all patients with C1-INH-HAE and are associated with severe pains lasting for many hours to several days [53]. In nC1-INH-HAE, the occurrence of abdominal angioedema attacks varies between the different types and appears to be more frequent in FXII-HAE and rather rare in PLG-HAE [33]. A small number of reports describe abdominal swellings as a rare and unusual feature of ACEi-AE [47, 55, 56]. Abdominal angioedema attacks are usually not seen in patients with MCM-AE, but a small rate of patients with CSU reports mild or moderate abdominal complaints [54].

The genitals are affected in most patients with BK-AE (i.e., C1-INH-HAE and C1-INH-AAE), although angioedema of the genitals is rare compared with other skin sites. In all other forms of AE, genital angioedema is infrequent.

Course and Duration of Swellings

In MCM-AE, the time between the onset of angioedema, often a tingling sensation, and the maximum of the swelling can be less than 30 min, but usually it takes 1 to 4 h. After the angioedema has fully developed, it slowly resolves and subsides within 12 to 24 h, in most cases. AE, in patients with BK-AE, usually develops at a slower pace, over the course of several hours [26, 57, 58]. However, some swellings develop rapidly, especially abdominal and laryngeal attacks. The reasons remain unclear but may be explained by the fact that the key symptoms, pain and difficulty in breathing, respectively, reach their maximum effect earlier than those of the peripheral swellings. In most patients with C1-INH-HAE or C1-INH-AAE, swellings progress for 6 to 24 h from the onset to reaching the maximum. Untreated C1-INH-HAE attacks rarely last less than 36 h but sometimes longer than 6 days, if left untreated. Reliable newer data are hard to find, as patients are advised to treat their attacks early and often do. There is very little information on the course of attacks in patients with nC1-INH-HAE. In patients with ACEi-AE, swellings develop usually within a few hours, typically 6 to 12 h; however, faster or slower progress to maximum has been described in many cases [59, 60]. Of note, the development of the swelling is not necessarily linear over time, but can progress more rapidly after a slow onset. Usually, swellings in patients with ACEi-AE resolve within 48 to 72 h.

Frequency of Swellings

The frequency of swellings underlies wide intraindividual and interindividual variations. In all types of AE, affected patients can develop swellings as often as several times per week, whereas others can go months and sometimes years without any attacks, although this is very rare. On average, patients with nC1-INH-HAE report less frequent episodes of swellings than other forms of BK-AE [61]. The median number of attacks in nC1-INH-HAE was reported to be approximately 5 per year, whereas C1-INH-HAE and C1-INH-AAE patients were reported to suffer from approximately 10 attacks per year [46, 61–64]. Patients with MCM-AE due to CSU are held to show the highest average frequency of swelling episodes. Of note, disease activity including rates of attacks, with the help of suitable tools such as the angioedema activity score (AAS, [65, 66]), has not yet been assessed and compared prospectively across patient population with MCM-AE and BK-AE.

Differences and Similarities In Clinical Features of Diseases That Manifest with MCM-AE and BK-AE

Prodromal Signs and Symptoms

AE prodromes are unique to BK-AE, specifically C1-INH-HAE. In up to 80% of patients with C1-INH-HAE, angioedema attacks are often, but not always, heralded by prodromal signs or symptoms [67–70]. Common prodromal signs and symptoms include typical erythema marginatum pain, fatigue, or nausea. Prodromes occur mostly within 6 h before an attack and must be strictly differentiated from the symptoms of the emerging actual attack. Prodromes have not been commonly described in other forms of AE, with the exception of unspecific prodromes in a small number of patients with FXII-HAE [71].

Triggers of Angioedema Attacks

Swellings in all types of AE have been reported to occur in response to inciting factors (triggers). What has to be kept in mind is that the assessment of the prevalence and relevance of triggers for selling attacks is difficult, as it relies on the patients’ perception of the relation between triggers and attacks. Triggers are often only reported, when patients suspect them to be linked to inducing swellings. Furthermore, many triggers such as stress are difficult to authenticate.

Emotional distress is held to be a relevant trigger of angioedema attacks in 21–23% of patients with C1-INH-HAE, which makes it the most frequent trigger in this form of AE [67, 72]. In most types of nC1-INH-HAE the role of stress as a trigger remains unclear, except in FXII-HAE, where, in two large patient populations, stress was found to be a trigger in approximately 50% of
the patients [71, 73]. MCM-AE, in patients with CSU, is widely held to be linked to emotional stress, and CSU is known to worsen with increased levels of stress [74]. However, the prevalence and relevance of stress as a trigger of angioedema episodes have not yet been well established. Physical exertion, acute viral infections, and foods are known triggers in subpopulations of patients with C1-INH-HAE and MCM-AE. A frequent trigger of BK-AE is mechanical trauma, such as pressure, vibrations, surgical manipulations (i.e., oral mucosal pressure during dental procedures), and physical contact during recreational sport [67, 72]. This kind of “reactive angioedema” at the site of preceding mechanical trauma seems to be specific for C1-INH-HAE and FXII-HAE as well as for symptomatic dermographism and delayed pressure urticaria, two forms of CIndU [72, 73, 75].

Drugs are frequent triggers of angioedema episodes, across all forms of both MCM-AE and BK-AE. ACE-inhibitors, the causative agents in ACEi-AE, are known to increase attack rates in patients with C1-INH-HAE, C1-INH-AAE, and FXII-HAE, but not MCM-AE [76, 77]. Estrogen treatment also drives disease activity in patients with C1-INH-HAE, and even more in nC1-INH-HAE. Patients with BK-AE should, therefore, avoid estrogen medication (i.e., oral contraceptives). ACE-inhibitors and thrombolytic treatments (with recombinant tissue plasminogen activators—rtPA) may also induce oro-pharyngeal AE due BK dysregulation. In MCM-AE patients with CSU, estrogens are only sporadically reported as triggers, although female patients sometimes see their menstrual cycle linked to disease activity.

MCM-AE is a frequent and well-known side effect of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly in patients with CSU. Clinical experience shows that the relevance of NSAIDs as triggers of swellings in patients with MCM-AE is widely restricted to their use as pain killers, antipyretics, and anti-inflammatory agents, i.e., in high doses, whereas low doses of NSAR, for example, acetylsalicylic acid used as an antithrombotic agent, rarely trigger swellings. NSAIDs do not trigger BK-mediated AE, but can, of course, induce MCM-mediated angioedema in patients with BK-AE.

Signs and Symptoms Linked to AE Including Wheals

MCM-AE, in most affected patients, is due to urticaria. At least two thirds of urticaria patients with MCM-AE also develop recurrent wheals (hives), whereas recurrent wheals (urticarial skin rash) are not a typical feature of any BK-AE type. Therefore, as a general rule, recurrent wheals with AE indicate MCM-AE due to chronic urticaria, most commonly CSU. Nevertheless, the absence of wheals does not rule out MCM-AE, as about 10% of patients with CSU, develop only AE and never have wheals. Urticaria is one of the most common dermatological diseases [78]. Most patients experience urticaria at least once in their lives, mostly acute spontaneous urticaria, which remits within days and weeks. Patients with BK-AE are equally susceptible to contracting urticaria as the general population. This has been shown in a recent publication of Rasmussen and coworkers, where a total of 22 patients (25%) with C1-INH-HAE reported former episodes of urticaria with wheals [70]. Therefore, the occurrence of wheals in the history or physical examination does not rule out BK-AE as a diagnosis.

Recurrent subcutaneous hemorrhage (petechiae) at sites of skin swellings occurring 1 or 2 days after the onset of the swellings was described in some FXII-HAE patients. The hemorrhages were limited to the site of the skin swelling [46, 71, 79]. This phenomenon does not happen in patients with MCM-AE.

Differences and Similarities in the Onset and Duration of Disease in MCM-AE and BK-AE

Onset of Disease

The age of onset of BK-AE varies widely. Patients with C1-INH-HAE are born with this trait, but they usually become symptomatic in the first two decades of life, on average around the age of 12 years. Patients with nC1-INH-HAE often start to develop swellings in the third decade of life, but the reported variations are very large. Patients with ACEi-AE or C1-INH-AAE are, on average, around 60 years of age when they first develop swellings. In contrast, MCM-AE can start at any age, but most patients are in their 30s or 40s when they first develop swelling episodes [47, 61, 80].

Duration of Disease

HAE as a genetic disease is a life-long condition. C1-INH-AAE persists throughout life or until therapeutic or spontaneous remission of the underlying disease. There is no data on ACEi-AE, but usually the establishment of the diagnosis goes along with the discontinuation of the ACE inhibitor. There is also little data on MCM-AE. Data from patients with CSU show that most patients are affected by angioedema for more than 1 year, 5 to 7 years on average, with a considerable number of patients affected for longer periods of time [81].
Conclusions, Open Questions and the Need for Further Studies

Here, we reviewed the similarities and differences of the mechanisms and clinical expression of BK-AE and MCM-AE. Knowledge of these differences, together with differences in laboratory markers, which are reviewed elsewhere [82], can help to reduce the rates of misdiagnosis and delayed diagnosis.

We are still lacking information on some important features and characteristics of AE, both for MCM-AE, BK-AE. Little is known, for example, about the histological features of BK-AE, the kinetics of cellular infiltration, and the cellular composition of the infiltrate. Other features are well characterized for both types of AE but are difficult to compare, based on the available information. Studies are available on MCM-AE and BK-AE and its association with other comorbidities, burden of disease, impact on sleep, and social, mental, and sexual health. More studies are required to compare these entities, controlling patients for age, gender, genetic background, and other important confounders, by using tools that are suitable for all AE patients such as the angioedema activity score (AAS) or the angioedema control test (AECT) [83, 84]). Ideally, such studies should be performed in a global setting and by professional networks, such as that of angioedema centers of reference and excellence (ACARE, [85]).

One of the biggest challenges in AE management in clinical practice is AE of unknown cause, i.e., AE in patients who do not fulfill the diagnostic criteria of known MCM-AE or BK-AE types. AE profiling by international guidelines, established AE type-specific biomarkers, may help to guide the diagnostic workup and advance the quality of treatments for affected patients.

Funding Open Access funding enabled and organized by Projekt DEAL. Intramural funding.

Compliance with Ethical Standards

Conflict of Interest Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Aplylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Cellnex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIMinnovation, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third HarmonicBio, UCB, and Uriach. Markus Magerl is or recently was a speaker and/or advisor for and/or has received research funding from BioCryst, CSL Behring, Kalvista, Novartis, Octapharma, Pharming, Sanofi/Regeneron, Shire/Takeda.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, Bowen T et al (2018) The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy 73(8):1575–1596. https://doi.org/10.1111/all.13384
2. Church MK, Kolkhir P, Metz M, Maurer M (2018) The role and relevance of mast cells in urticaria. Immunol Rev 282(1):232–247. https://doi.org/10.1111/imr.12632
3. Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T (2020) Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 75(2):423–432. https://doi.org/10.1111/all.14037
4. Maurer M, Costa C, Gimenez-Arnau A, Guillet G, Labrador-Horillo M, Lapeere H et al (2020) Antihistamine-resistant chronic spontaneous urticaria remains untreated: 2-year data from the AWARE study. Clin Exp Allergy. https://doi.org/10.1111/cea.13716
5. Sussman G, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C et al (2018) Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy 73(8):1724–1734. https://doi.org/10.1111/all.13430
6. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW et al (2011) Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 66(3):317–330. https://doi.org/10.1111/j.1398-9995.2010.02496.x
7. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, Gonzalez-Aveledo L, Maurer M (2017) Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 31(6):964–971. https://doi.org/10.1111/jdv.12661
8. Mellerowicz EJ, Asady A, Maurer M, Altrichter S (2019) Angioedema frequently occurs in cholinergic urticaria. J Allergy Clin Immunol Pract 7(4):1355–1357 e1351. https://doi.org/10.1016/j.jaip.2018.10.013
9. Schoepke N, Mlynak A, Weller K, Church MK, Maurer M (2015) Symptomatic dermatographism: an inadequately described disease. J Eur Acad Dermatol Venereol 29(4):708–712. https://doi.org/10.1111/jdv.12661
10. Hallgren J, Hellman L, Maurer M, Nilsson GP, Wernersson S, Abrikn M, Peijler G (2020) Novel aspects of mast cell and basophil function: highlights from the 9th meeting of the European Mast Cell and Basophil Research Network (EMBRN)-A Marcus Wallenberg Symposium. Allergy 75(3):707–708. https://doi.org/10.1111/all.14065
11. Maurer M, Pucillo C (2018) What we know (and don’t know) about the biology and functions of mast cells and basophils. Immunol Rev 282(1):5–7. https://doi.org/10.1111/imr.12645
12. Maurer M, Koberle M, Metz M, Biedermann T (2019) Mast cells: Promoters of health and modulators of disease. J Allergy
21. Kuhn H, Kolkphir P, Babina M, Dull M, Frischbuchter S, Fok JS, Jiao Q et al (2020) Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2020.08.027

22. Altrichter S, Frischbuchter S, Fok JS, Jiao Q, Kolkphir P, Skov PS, Metz C, Church MK, Maurer M (2020) The role of eosinophilins in chronic spontaneous urticaria. J Allergy Clin Immunol 145(6):1510–1516. https://doi.org/10.1016/j.jaci.2020.03.005

23. Kolkphir P, Church MK, Altrichter S, Skov PS, Hawro T, Frischbuchter S, Metz C, Maurer M (2020) Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract 8(1):318–325 e315. https://doi.org/10.1016/j.jcap.2019.08.025

24. Folkerts J, Gaudenzio N, Maurer M, Hendriks RW, Stadhouders R, Tam SY, Galli SJ (2020) Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy. Nat Protoc 15(3):1285–1310. https://doi.org/10.1038/s41596-019-0288-6

25. Kolkphir P, Church MK, Weller K, Metz C, Schmetzer O, Maurer M (2017) Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol 139(6):1772–1781 e1771. https://doi.org/10.1016/j.jaci.2016.08.050

26. Maurer M, Eyerich K, Eyerich S, Ferrer M, Greve J, Hartmann K, Jakob T et al (2020) Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol 181(5):321–333. https://doi.org/10.1159/000507218

27. Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, Maurer M (2018) IL-24 is a common and specific autoantigen in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract 8(1):318–325 e315. https://doi.org/10.1016/j.jcap.2019.08.025

28. Altrichter S, Peter HJ, Pisarevskaja D, Metz C, Martus P, Maurer M (2011) IgE mediated autoallergy against thyroid peroxidase—a novel pathomechanism of chronic spontaneous urticaria? PLoS One 6(4):e14794. https://doi.org/10.1371/journal.pone.0014794

29. Altrichter S, Zampelli V, Ellrich A, Zhang K, Church MK, Maurer M (2020) IgM and IgA in addition to IgG autoantibodies against FcεrepsilonR1alpha are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. https://doi.org/10.1111/1411.2017.10.035

30. Schoepke N, Asero R, Ellrich A, Ferrer M, Gimenez-Arnau A, C EHJ, Jakob T, et al (2019) Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study. Allergy 74(12):2427–2436. https://doi.org/10.1111/13949

31. Aygoren-Pursun E, Magerl M, Maetzel A, Maurer M (2018) Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 13(1):75. https://doi.org/10.1186/s13023-018-0815-5

32. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballerio T et al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69(5):602–616. https://doi.org/10.1111/all.12380

33. Buttgereit T, Maurer M (2019) Classification and pathophysiology of angioedema. Hautarzt 70(2):84–91. https://doi.org/10.1007/s00105-018-4318-z

34. Bork K, Barnstedt SE, Koch P, Traupe H (2000) Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356(9225):213–217. https://doi.org/10.1016/S0140-6736(00)02483-1

35. Bork K, Wulff K, Steinmuller-Magin L, Braenne I, Staubach-Penz R, Witzke G, Hardt J (2018) Hereditary angioedema with a mutation in the plasminogen gene. Allergy 73(2):442–450. https://doi.org/10.1111/all.13270

36. Bafunno V, Firinu D, D'Amelio M, Cordisco G, Loffredo S, Leccese A, Bova M et al (2018) Mutation of the angiopeptin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 141(3):1009–1017. https://doi.org/10.1016/j.jaci.2017.05.020

37. Bork K, Wulff K, Rossmann H, Steinmuller-Magin L, Braenne I, Witzke G, Hardt J (2019) Hereditary angioedema cosegregating with a novel kinase-1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy 74(12):2479–2481. https://doi.org/10.1111/all.13869

38. Ariano A, D’Amelio M, Bova M, Bellanti F, Loffredo S, D’Andrea G, Intrieri M et al (2020) A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy. https://doi.org/10.1111/all.14454

39. Bork K, Machnic T, Wulff K, Witzke G, Prusty S, Hardt J (2020) Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis 15(1):289. https://doi.org/10.1186/s13023-020-01570-x

40. Gobert D, Paule R, Ponard D, Levy P, Fremeaux-Bacchi V, Bouillet L, Boccon-Gibod I et al (2016) A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients. Medicine (Baltimore) 95(33):e4363. https://doi.org/10.1097/MD.0000000000004363

41. Zanchelli A, Azin GM, Wu MA, Suffritti C, Magoni L, Caccia S, Perego F, Vacchini R, Cicardi M (2017) Diagnosis, course, and management of angioedema in patients with acquired C1 inhibitor deficiency. J Allergy Clin Immunol Pract 5(3):1307–1313. https://doi.org/10.1016/j.jcap.2016.12.032

42. Bas M, Greve J, Strassen U, Khosravani F, Hoffmann TK, Kojda G (2015) Angioedema induced by cardiovascular drugs: new players join old friends. Allergy 70(10):1196–1200. https://doi.org/10.1111/all.13023

43. Buttgereit T, Maurer M (2019) Classification and pathophysiology of angioedema. Allergy 70(10):1196–1200. https://doi.org/10.1111/all.13023

44. Beaoudin E, Defendi F, Picaud J, Drouet C, Ponard D, Moneret-Vautrin DA (2014) Iatrogenic angioedema associated with diabetes and treatment with ACE inhibitors. J Allergy 139(1):73–77. https://doi.org/10.1016/j.jaci.2013.09.035

45. Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, Bullardo G (2011) Bradykinin in health and disease: evidence from the proceedings of the Bradykinin Symposium 2012, Berlin 23–24 August 2012. Inflamm Res 63(3):173–178. https://doi.org/10.1007/s00011-013-0693-1
55. Saameli E, Eskes TK (1962) Bradykinin and cardiovascular system: estimation of half-life. Am J Physiol 203:261–265. https://doi.org/10.1152/ajplegacy.1962.203.2.261

56. SIA, K AP (1989) The Mechanism of Degradation of Bradykinin (Lysyl-Bradykinin) in Human Serum. In: K. A, H. M, S. F (eds) Kinins V. Advances in Experimental Medicine and Biology, vol 247. A. Springer, Boston, MA

57. Maurer M, Magerl M (2020) How to control recurrent angioedema using monoclonal antibody therapies? Expert Opin Biol Ther 20(1):1–4. https://doi.org/10.1080/14712598.2020.1691994

58. Craig TJ, Bernstein JA, Parkas H, Bouillet L, Boccon-Gibod I (2014) Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol 165(2):119–127. https://doi.org/10.1159/000368404

59. Atalay E, Ozdemir MT, Cisgar G, Omurcu F, Aslan N, Yildiz M, Gey ZB (2015) Angiotensin converting enzyme inhibitor-related angioedema: a case of an unexpected death. Iran J Allergy Asthma Immunol 14(6):642–645

60. Chiu AG, Newkirk KA, Davidson BJ, Burningham AR, Krowiak EJ, Deeb ZE (2001) Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 110(9):834–840. https://doi.org/10.1177/000348940111000906

61. Mansi M, Zanichelli A, Coerefzza A, Sufritti C, Wu MA, Vacchini R, Stieber C et al (2015) Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med 277(5):585–593. https://doi.org/10.1111/joim.12304

62. Belbezzer A, Hardy G, Marlu R, Defendi F, Dumestre Perard C, Boccon-Gibod I et al (2018) Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families. Allergy 73(11):2237–2239. https://doi.org/10.1111/all.13543

63. Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O et al (2017) Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey. Clin Exp Immunol 188(1):148–153. https://doi.org/10.1111/cei.12910

64. Stoneh HS, Weber-Chrysochoou C, Helbling A, Scherer K, Grendelmeier PS, Wulleim WA (2016) Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study. Orphanet J Rare Dis 11:43. https://doi.org/10.1186/s13023-016-0423-1

65. Kulthan K, Chuloojanamonti L, Rujthararanawong C, Weerasubpong P, Weller K, Maurer M (2019) Angioedema activity score (AAS): a valid and reliable tool to use in asian patients. Biomed Res Int 2019:9157895. https://doi.org/10.1155/2019/9157895

66. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, Metz M, Staubach P, Maurer M (2013) Development, validation, and initial results of the angioedema activity score. Allergy 68(9):1185–1192. https://doi.org/10.1111/all.12209

67. Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V, Group IOSS (2016) Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol 26(6):383–386. https://doi.org/10.18176/jiaci.0102

68. Magerl M, Doumoulakis G, Kalkounou I, Weller K, Church MK, Kreuz W, Maurer M (2014) Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol 39(3):298–303. https://doi.org/10.1111/ced.12285

69. Prematta MJ, Kemp JG, Gibbs JG, Mende C, Rhoads C, Craig TJ (2009) Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 30(5):506–511. https://doi.org/10.2500/aap.2009.30.3279

70. Rasmussen ER, de Freitas PV, Bygum A (2016) Urticaria and prodromal symptoms including erythema marginatum in Danish patients with hereditary angioedema. Acta Derm Venereol 96(3):373–376. https://doi.org/10.2340/00015555-2233

71. Pinerio-Saavedra M, Gonzalez-Quevedo T, de San S, Pedro B, Alcaraz C, Bobadilla-Gonzalez F, Fernandez-Vieira L, Hinojosa B, Garcia-Lozano R (2016) Hereditary angioedema with F12 mutation: clinical features and enzyme polymorphisms in 9
Southwestern Spanish families. Ann Allergy Asthma Immunol 117(5):520–526. https://doi.org/10.1016/j.anai.2016.09.001

72. Zottor Z, Csuka D, Szabo E, Czaller I, Nebenfuhrer Z, Temesszentandrasi G, Fust G, Varga L, Farkas H (2014) The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 9:44. https://doi.org/10.1186/1750-1172-9-44

73. Veronez CL, Moreno AS, Constantino-Silva RN, Maia LSM, Ferriani MPL, Castro FFM, Valle SR, et al. (2018) Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families. J Allergy Clin Immunol Pract 6 (4):1209–1216 e1208. https://doi.org/10.1016/j.jaip.2017.09.025

74. Schut C, Magerl M, Hawro T, Kupler J, Rose M, Gieler U, Maurer M, Peters EMJ (2020) Disease activity and stress are linked in a subgroup of chronic spontaneous urticaria patients. Allergy 75(1):224–226. https://doi.org/10.1111/all.14015

75. Abajian M, Schoepke N, Altrichter S, Zuberbier T, Maurer M (2014) Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am 34(1):73–88. https://doi.org/10.1016/j.iac.2013.09.010

76. Craig T (2020) Triggers and short-term prophylaxis in patients with hereditary angioedema. Allergy Asthma Proc 41(6):S30–S34. https://doi.org/10.2500/aap.2020.41.200058

77. Bork K, Wulff K, Witzke G, Hardt J (2017) Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy 72(2):320–324. https://doi.org/10.1111/all.13076

78. Ballmer-Weber BK, Kundig TM (2010) Urticaria—the most frequent dermatological disease. Ther Umsch 67(4):167–173. https://doi.org/10.1024/0040-5930/a00030

79. Taya J, Veronez CLL, Pesquero JBB, Bork K, Grumach AS (2020) Uncommon signs associated with hereditary angioedema with normal C1 inhibitor. J Invest Allergol Clin Immunol:0. https://doi.org/10.18176/jiaci.0509

80. Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C, Deroux A, Bouillet L (2016) Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol 185(1):81–85. https://doi.org/10.1111/cei.12789

81. Maurer M (2018) Patients with h1-antihistamine-resistant chronic spontaneous urticaria have long disease duration and show little improvement in disease characteristics and burden with time. In: EAACI, Munich. Poster Discussion Sessions

82. Belbezier A, Bocquet A, Bouillet L (2020) Idiopathic angioedema: current challenges. J Asthma Allergy 13:137–144. https://doi.org/10.2147/JAA.S205709

83. Weller K, Donoso T, Magerl M, Aygoren-Pursun E, Staubach P, Martinez-Saguer I, Hawro T et al (2019) Development of the Angioedema Control Test (AECT)—a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy. https://doi.org/10.1111/all.14144

84. Weller K, Donoso T, Magerl M, Aygoren-Pursun E, Staubach P, Martinez-Saguer I, Hawro T, et al (2020) Validation of the Angioedema Control Test (AECT)—a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract 8 (6):2050–2057 e2054. https://doi.org/10.1016/j.jaip.2020.02.038

85. Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, Arnaout R et al (2020) Definition, aims, and implementation of GA(2) LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy 75(8):2115–2123. https://doi.org/10.1111/all.14293

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.